LT3043803T - Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas - Google Patents

Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas

Info

Publication number
LT3043803T
LT3043803T LTEPPCT/US2014/054930T LT14054930T LT3043803T LT 3043803 T LT3043803 T LT 3043803T LT 14054930 T LT14054930 T LT 14054930T LT 3043803 T LT3043803 T LT 3043803T
Authority
LT
Lithuania
Prior art keywords
nucleotide
nucleoside compositions
nucleoside
compositions
Prior art date
Application number
LTEPPCT/US2014/054930T
Other languages
English (en)
Inventor
Dennis Liotta
George Painter
Gregory BLUEMLING
Abel De La Rosa
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of LT3043803T publication Critical patent/LT3043803T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2014/054930T 2013-09-11 2014-09-10 Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas LT3043803T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361876473P 2013-09-11 2013-09-11
US201461923317P 2014-01-03 2014-01-03
US201461986577P 2014-04-30 2014-04-30
PCT/US2014/054930 WO2015038596A1 (en) 2013-09-11 2014-09-10 Nucleotide and nucleoside compositions and uses related thereto

Publications (1)

Publication Number Publication Date
LT3043803T true LT3043803T (lt) 2022-08-10

Family

ID=52666219

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2014/054930T LT3043803T (lt) 2013-09-11 2014-09-10 Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas

Country Status (12)

Country Link
US (4) US10149859B2 (lt)
EP (2) EP3043803B1 (lt)
JP (4) JP6762873B2 (lt)
DK (1) DK3043803T3 (lt)
ES (1) ES2927955T3 (lt)
HR (1) HRP20220911T1 (lt)
LT (1) LT3043803T (lt)
PL (1) PL3043803T3 (lt)
SI (1) SI3043803T1 (lt)
TW (1) TW201542581A (lt)
UY (1) UY35732A (lt)
WO (1) WO2015038596A1 (lt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027929B1 (ru) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Нуклеозиды на основе урацила и спирооксетана
PT3150616T (pt) 2012-11-16 2017-06-09 Univ College Cardiff Consultants Ltd Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
HRP20220911T1 (hr) 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
WO2015200219A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TN2016000566A1 (en) * 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015198058A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
US10683319B2 (en) * 2014-12-15 2020-06-16 Emory University Phosphoramidates for the treatment of hepatitis B virus
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
GEP20247600B (en) 2015-03-06 2024-02-26 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
CN106674297A (zh) * 2015-11-11 2017-05-17 中国科学院生态环境研究中心 具有抗癌活性的新型krn7000类似物及合成方法
WO2017155923A1 (en) * 2016-03-07 2017-09-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
AU2017319260B2 (en) 2016-08-31 2020-01-30 Fujifilm Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
JP7016170B2 (ja) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 ヌクレオシド誘導体及びその利用
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
US10688112B2 (en) 2017-07-13 2020-06-23 Emory University Lipid disulfide prodrugs and uses related thereto
EP3712160A4 (en) 2017-10-31 2021-09-01 Yamasa Corporation NUCLEOSIDE DERIVATIVE AND ASSOCIATED USE
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
CA3087192A1 (en) * 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
CN111836823B (zh) * 2018-03-09 2023-06-30 国立研究开发法人科学技术振兴机构 β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN110655546B (zh) * 2018-12-18 2023-05-16 安徽贝克制药股份有限公司 索非布韦衍生物及其制备方法和应用
CN109503688A (zh) * 2018-12-21 2019-03-22 佛山科学技术学院 具有抑制病毒复制活性的核苷磷酸长链酯类似物、制备方法及其药物用途
KR20240113860A (ko) 2019-04-05 2024-07-23 가부시기가이샤 닛뽕쇼꾸바이 가교형 인공 뉴클레오시드의 제조
CN110204584B (zh) * 2019-06-17 2022-09-09 大连大学 一种4-s-2’,3’,5’-o-三乙酰基尿苷合成方法
CN110105416B (zh) * 2019-06-17 2022-07-12 大连大学 一种4-S-5-Br-2’，3’,5’-O-三乙酰基尿苷合成方法
AU2020334152A1 (en) 2019-08-22 2022-03-24 Emory University Nucleoside prodrugs and uses related thereto
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
JP7429799B2 (ja) 2020-02-18 2024-02-08 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR102145197B1 (ko) * 2020-03-10 2020-08-18 부광약품 주식회사 코로나바이러스를 치료하기 위한 l-뉴클레오사이드의 용도
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2022081823A1 (en) * 2020-10-14 2022-04-21 Temple University -Of The Commonwealth System Of Higher Education Pharmacologic approach for suppression of coronaviruses
CN112778356B (zh) * 2020-12-26 2022-07-01 山东日兴新材料股份有限公司 一种三(三溴新戊基)磷酸酯阻燃剂的一锅法合成工艺
CN112661802B (zh) * 2021-01-25 2022-05-13 阿里生物新材料（常州）有限公司 一种3′-甲氧基鸟苷的合成方法
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
EP4323362A1 (en) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN112979733B (zh) * 2021-04-25 2021-09-10 南京颐媛生物医学研究院有限公司 抗乙肝病毒的化合物及其制备方法和应用
EP4333859A1 (en) * 2021-05-05 2024-03-13 Emory University Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CN113278041B (zh) * 2021-07-16 2021-10-19 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN113501853B (zh) * 2021-09-13 2021-12-07 南京颐媛生物医学研究院有限公司 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途
CN113735927B (zh) * 2021-10-18 2024-06-28 厦门蔚扬药业有限公司 一种核苷酸类似物及其制备方法和用途
WO2023086557A1 (en) * 2021-11-11 2023-05-19 Emory University Nucleosides for the treatment of dna virus infections
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116554249A (zh) * 2022-01-28 2023-08-08 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
WO2023178228A1 (en) * 2022-03-16 2023-09-21 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions
WO2024137577A1 (en) * 2022-12-19 2024-06-27 Ohio State Innovation Foundation Multiparametric integrated molecular detection of viral antigens and viral nucleic acids
WO2024167952A1 (en) * 2023-02-08 2024-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oxidatively cleavable organophosphate drugs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
DE2041735A1 (de) * 1970-08-22 1972-02-24 Merck Patent Gmbh Thio-pyrimidin-derivate
US3975374A (en) 1970-12-21 1976-08-17 The Upjohn Company Process for preparing 2-thiouracil nucleosides
JPS4947379A (lt) 1972-09-12 1974-05-08
PL107865B1 (pl) 1977-04-27 1980-03-31 Polska Akademia Nauk Instytut Method of obtaining styrene oxide sposob otrzymywania tlenku styrenu
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US4954485A (en) 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU722214B2 (en) 1995-06-07 2000-07-27 Centre National De La Recherche Scientifique (Cnrs) Nucleosides with anti-hepatitis B virus activity
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
JPH107694A (ja) * 1996-06-21 1998-01-13 Toagosei Co Ltd ３’−アミノ−２−チオピリミジンヌクレオシド
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE69943314D1 (de) 1998-02-12 2011-05-12 Kapil N Bhalla Sphingolipid-derivate und verfahren zu deren verwendung
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6461422B1 (en) * 2000-01-27 2002-10-08 Chartpak, Inc. Pressure sensitive ink jet media for digital printing
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1346724A4 (en) * 2000-12-26 2004-11-17 Mitsubishi Pharma Corp REMEDIES FOR HEPATITIS C
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
JP2005536440A (ja) * 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
PL197669B1 (pl) * 2002-02-28 2008-04-30 Pan Inst Biochemii I Biofizyki Nowe analogi 2',3'-dideoksy-3'-fluorotymidyny o aktywności przeciwko wirusom (54) ludzkiego niedoboru immunologicznego HIV-1 i HIV-2, sposób ich wytwarzania oraz zawierające je środki farmaceutyczne
KR20050006221A (ko) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Ｃ형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체
TW200500374A (en) 2002-06-28 2005-01-01 Idenlx Cayman Ltd 2' and 3' -nucleoside produrgs for treating flavivridae infections
US20040035547A1 (en) 2002-08-20 2004-02-26 3M Innovative Properties Company Metal matrix composites, and methods for making the same
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
HUP0600042A3 (en) 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
MX2010002904A (es) 2007-09-17 2010-06-02 Abbott Lab N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
WO2009039127A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
JP5571167B2 (ja) 2009-03-25 2014-08-13 アッヴィ・インコーポレイテッド 抗ウイルス組成物およびこの使用
CA2986195A1 (en) 2009-03-25 2010-09-30 Abbvie Inc. Substituted aryl antivrial compounds and uses thereof
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DK2455376T3 (en) 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
JP5717768B2 (ja) 2010-03-10 2015-05-13 アッヴィ・バハマズ・リミテッド 固体組成物
US8691775B2 (en) * 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
MX2012014301A (es) 2010-06-07 2013-04-29 Enanta Pharm Inc Inhibidores macrociclicos de serina proteasa de hepatitis c.
CR20180412A (es) 2010-07-16 2018-11-01 Abbvie Ireland Unlimited Co Proceso para preparar compuestos antivirales
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
TWI451439B (zh) 2010-12-10 2014-09-01 Phison Electronics Corp 記憶體儲存裝置、其記憶體控制器與資料寫入方法
EP2651924A1 (en) 2010-12-16 2013-10-23 Abbvie Inc. Anti-viral compounds
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
HRP20220911T1 (hr) * 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
US10683319B2 (en) * 2014-12-15 2020-06-16 Emory University Phosphoramidates for the treatment of hepatitis B virus

Also Published As

Publication number Publication date
JP2022081641A (ja) 2022-05-31
US20240173345A1 (en) 2024-05-30
US11166973B2 (en) 2021-11-09
PL3043803T3 (pl) 2022-11-07
US20220296626A1 (en) 2022-09-22
HRP20220911T1 (hr) 2022-10-28
EP3043803A1 (en) 2016-07-20
US11857560B2 (en) 2024-01-02
SI3043803T1 (sl) 2022-09-30
JP7508501B2 (ja) 2024-07-01
JP2020143073A (ja) 2020-09-10
DK3043803T3 (da) 2022-08-01
US10149859B2 (en) 2018-12-11
JP6762873B2 (ja) 2020-09-30
EP3043803B1 (en) 2022-04-27
EP4094767A1 (en) 2022-11-30
TW201542581A (zh) 2015-11-16
EP3043803A4 (en) 2017-03-29
JP2016530313A (ja) 2016-09-29
ES2927955T3 (es) 2022-11-14
WO2015038596A1 (en) 2015-03-19
JP2024123107A (ja) 2024-09-10
US20160220595A1 (en) 2016-08-04
US20190298750A1 (en) 2019-10-03
UY35732A (es) 2015-06-30
JP7045411B2 (ja) 2022-03-31

Similar Documents

Publication Publication Date Title
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
LT3043803T (lt) Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
HK1220463A1 (zh) 修飾的核苷或核苷酸
HK1224229A1 (zh) 取代的核苷，核苷酸及其類似物
HK1222178A1 (zh) 取代的核苷、核苷酸及其類似物
IL245014A0 (en) Nucleosides, modified nucleotides and their analogs
HK1215595A1 (zh) 白細胞介素- 藥物組合物和使用方法
HK1210619A1 (en) Novel nucleoside phosphoramidate compound and use thereof
GB201313235D0 (en) Antiviral Compositions Methods and Animals
EP2953474A4 (en) COMPOSITIONS AND METHODS
GB201308072D0 (en) Compositions and methods
EP2957567A4 (en) NUCLEOSIDE AND NUCLEOTIDE WITH AN NITROGENIC HETEROCYCLIC STRUCTURE
EP2928876A4 (en) NUCLEOSID KINASEBYPASS COMPOSITIONS AND METHOD
GB201321693D0 (en) Composition and uses thereof
HK1220388A1 (zh) 尿苷核苷衍生物、組合物及使用方法
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201305813D0 (en) Compositions and methods
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
IL233475A (en) Carbocyclic nucleosides, preparations containing them and their uses
ZA201500493B (en) Glycoconjugation processes and compositions
GB201308242D0 (en) Compositions and uses thereof
GB201312393D0 (en) Compositions and Methods
GB201301022D0 (en) Composition and uses thereof